Evaluate Your CAR-T Therapies in Highly Predictive Translational Models
Patient-derived xenograft (PDX) models allow in vivo preclinical CAR-T evaluation in highly predictive models which preserve the heterogeneous pathological and genetic characteristics of the original patient tumors. This provides robust and highly translatable data to drive forward preclinical CAR-T therapy research.
Why PDX for CAR-T Therapy Evaluation?
CrownBio's HuPrime® PDX CAR-T therapy Translational Platform provides the full package of:
- A large, diverse collection of 2,500 well-characterized models, to access a wide range of CAR-T targets
- Quick and easy model selection using mRNA expression data from
- Model expression validation via IHC, confirming antigen expression
- Efficacy testing in highly predictive models, which truly mimic human disease and response
We have completed case studies in solid tumors, targeting GPC3 in lung cancer, and MSLN in pancreatic cancer.
Contact us to discuss your CAR-T therapy project needs, and to find out more on our fully comprehensive PDX CAR-T therapy platform.